Suppr超能文献

2023年炎症性肠病在加拿大的影响:特殊人群——老年人中的炎症性肠病

The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations-IBD in Seniors.

作者信息

Shaffer Seth R, Kuenzig M Ellen, Windsor Joseph W, Bitton Alain, Jones Jennifer L, Lee Kate, Murthy Sanjay K, Targownik Laura E, Peña-Sánchez Juan-Nicolás, Rohatinsky Noelle, Ghandeharian Sara, Tandon Parul, St-Pierre Joëlle, Natt Navneet, Davis Tal, Weinstein Jake, Im James H B, Benchimol Eric I, Kaplan Gilaad G, Goddard Quinn, Gorospe Julia, Bergevin Maxime, Silver Ken, Bowles Dawna, Stewart Margaret, Pearlstein Marsha, Dawson Elizabeth H, Bernstein Charles N

机构信息

Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.

University of Manitoba IBD Clinical and Research Centre, Winnipeg, Manitoba, Canada.

出版信息

J Can Assoc Gastroenterol. 2023 Sep 5;6(Suppl 2):S45-S54. doi: 10.1093/jcag/gwad013. eCollection 2023 Sep.

Abstract

Approximately one out of every 88 seniors has inflammatory bowel disease (IBD), and this is expected to increase in the future. They are more likely to have left-sided disease in ulcerative colitis, and isolated colonic disease in Crohn's disease; perianal disease is less common. Other common diagnoses in the elderly must also be considered when they initially present to a healthcare provider. Treatment of the elderly is similar to younger persons with IBD, though considerations of the increased risk of infections and malignancy must be considered when using immune modulating drugs. Whether anti-TNF therapies increase the risk of infections is not definitive, though newer biologics, including vedolizumab and ustekinumab, are thought to be safer with lower risk of adverse events. Polypharmacy and frailty are other considerations in the elderly when choosing a treatment, as frailty is associated with worse outcomes. Costs for IBD-related hospitalizations are higher in the elderly compared with younger persons. When elderly persons with IBD are cared for by a gastroenterologist, their outcomes tend to be better. However, as elderly persons with IBD continue to age, they may not have access to the same care as younger people with IBD due to deficiencies in their ability to use or access technology.

摘要

每88名老年人中约有1人患有炎症性肠病(IBD),预计未来这一比例还会上升。他们在溃疡性结肠炎中更易患左侧疾病,在克罗恩病中更易患孤立性结肠疾病;肛周疾病则较为少见。老年人最初就诊于医疗服务提供者时,还必须考虑其他常见诊断。老年人IBD的治疗与年轻人相似,不过在使用免疫调节药物时,必须考虑感染和恶性肿瘤风险增加的因素。抗TNF疗法是否会增加感染风险尚无定论,不过包括维多珠单抗和乌司奴单抗在内的新型生物制剂被认为更安全,不良事件风险更低。在为老年人选择治疗方案时,还需考虑多重用药和身体虚弱的问题,因为身体虚弱与较差的治疗结果相关。与年轻人相比,老年人IBD相关住院费用更高。当IBD老年患者由胃肠病学家照料时,他们的治疗结果往往更好。然而,随着IBD老年患者年龄的增长,由于他们使用或获取技术的能力不足,可能无法获得与IBD年轻患者相同的护理。

相似文献

1
The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations-IBD in Seniors.
J Can Assoc Gastroenterol. 2023 Sep 5;6(Suppl 2):S45-S54. doi: 10.1093/jcag/gwad013. eCollection 2023 Sep.
2
The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S17-S33. doi: 10.1093/jcag/gwy055. Epub 2018 Nov 2.
3
The Impact of Inflammatory Bowel Disease in Canada 2018: IBD in Seniors.
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S68-S72. doi: 10.1093/jcag/gwy051. Epub 2018 Nov 2.
4
The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S49-S67. doi: 10.1093/jcag/gwy056. Epub 2018 Nov 2.
5
Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBD.
J Can Assoc Gastroenterol. 2021 Nov 5;4(Suppl 2):S34-S39. doi: 10.1093/jcag/gwab025. eCollection 2021 Dec.
6
The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD.
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S73-S80. doi: 10.1093/jcag/gwy053. Epub 2018 Nov 2.
7
The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care.
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S34-S41. doi: 10.1093/jcag/gwy050. Epub 2018 Nov 2.
10
The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology.
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S6-S16. doi: 10.1093/jcag/gwy054. Epub 2018 Nov 2.

引用本文的文献

1
The global burden of inflammatory bowel disease: from 2025 to 2045.
Nat Rev Gastroenterol Hepatol. 2025 Jul 18. doi: 10.1038/s41575-025-01097-1.
2
Compounding Prevalence of Inflammatory Bowel Disease in a 2024 Population-Based Study From Canterbury, New Zealand.
JGH Open. 2025 May 30;9(6):e70192. doi: 10.1002/jgh3.70192. eCollection 2025 Jun.
3
Global evolution of inflammatory bowel disease across epidemiologic stages.
Nature. 2025 Apr 30. doi: 10.1038/s41586-025-08940-0.
5
Identification and prioritization of patient-centred strategies to enhance IBD-related care for older adults: a modified Delphi approach.
J Can Assoc Gastroenterol. 2024 Jul 6;7(5):384-392. doi: 10.1093/jcag/gwae021. eCollection 2024 Oct.

本文引用的文献

2
Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases.
Am J Gastroenterol. 2022 Mar 1;117(3):462-469. doi: 10.14309/ajg.0000000000001619.
6
Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults.
Clin Gastroenterol Hepatol. 2022 Jun;20(6):1299-1305.e5. doi: 10.1016/j.cgh.2021.08.047. Epub 2021 Sep 3.
9
Efficacy of Vedolizumab in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients.
Inflamm Bowel Dis. 2022 May 4;28(5):734-744. doi: 10.1093/ibd/izab163.
10
An Australian Real-World Study of Treatment Persistence of Ustekinumab in Crohn's Disease.
Biologics. 2021 Jun 16;15:237-245. doi: 10.2147/BTT.S310076. eCollection 2021.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验